HOME > ARCHIVE
ARCHIVE
- Fuso: Profits Marked for 1st Time in 3 Years
December 1, 2003
- SEMI-ANNUAL BUSINES RESULTS
December 1, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
November 24, 2003
- Santen: Overall Sales Down Slightly from Sluggish Domestic Sales
November 24, 2003
- Statement on Proper Use of Iressa Issued by JLCS
November 24, 2003
- Ono: Sales Increase 2.8%, Profits Up 3.9%
November 24, 2003
- Micardis Exerts Hypotensive Effects for 24-hour: JSH Meeting
November 24, 2003
- Dainippon: Rapid Drop in Sales of Gatiflo Hurts Sales, Profits
November 24, 2003
- Home Blood Pressure GL Compiled by JSH
November 24, 2003
- Tanabe Seiyaku: 9.7% Increase in Net Profits Despite Sales Drop
November 24, 2003
- NEW PRODUCTS
November 24, 2003
- Shionogi: Sales Plunge 44.3%, but Profits Up
November 24, 2003
- Japan Adult Guardianship Law Association Inaugurated
November 24, 2003
- Chugai: Cost-cutting Efforts Produce Better-than-Expected Profits
November 24, 2003
- REGULATORY NEWS IN BRIEF
November 24, 2003
- Yamanouchi: Sales Up 2.8%, Attributable to Sales Growth of Harnal, Lipitor
November 24, 2003
- Council for Regulatory Reform May Be Replaced with More Powerful Machine: Mr Miyauchi
November 24, 2003
- Sankyo: Mevalotin Boosts Domestic, Overseas Sales
November 24, 2003
- FPMAJ Wants Gov't to Maintain Price Reduction Rules for Long-Listed Drugs
November 24, 2003
- Semi-annual Business Results
November 24, 2003
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
